Three FGFR inhibitors are currently approved for clinical use by FDA: erdafitinib for metastatic or locally advanced urothelial carcinoma with FGFR3 alterations; pemigatinib and futibatinib for metastatic or locally advanced, unresectable and earlier treated cholangiocarcinoma with FGFR2 fusion or rearrangement, and pemigatinib also for relapsed or refractory myeloid or lymphoid neoplasms with FGFR1 rearrangements [58, 59]. This evidence concerns the gene FGFR2 and urothelial carcinoma.